LU92213I2 - Insuline dégludec sous toutes les formes protégéespar le brevet de base - Google Patents

Insuline dégludec sous toutes les formes protégéespar le brevet de base

Info

Publication number
LU92213I2
LU92213I2 LU92213C LU92213C LU92213I2 LU 92213 I2 LU92213 I2 LU 92213I2 LU 92213 C LU92213 C LU 92213C LU 92213 C LU92213 C LU 92213C LU 92213 I2 LU92213 I2 LU 92213I2
Authority
LU
Luxembourg
Prior art keywords
insulin degludec
basic patent
forms protected
protected
forms
Prior art date
Application number
LU92213C
Other languages
English (en)
Other versions
LU92213I9 (fr
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of LU92213I2 publication Critical patent/LU92213I2/fr
Publication of LU92213I9 publication Critical patent/LU92213I9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
LU92213C 2003-08-05 2013-06-10 Insuline dégludec sous toutes les formes protégéespar le brevet de base LU92213I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301129 2003-08-05
US49545103P 2003-08-14 2003-08-14
EP04739008A EP1660531A2 (fr) 2003-08-05 2004-07-22 Nouveaux derives de l'insuline

Publications (2)

Publication Number Publication Date
LU92213I2 true LU92213I2 (fr) 2013-08-23
LU92213I9 LU92213I9 (fr) 2018-11-19

Family

ID=34117520

Family Applications (2)

Application Number Title Priority Date Filing Date
LU92213C LU92213I2 (fr) 2003-08-05 2013-06-10 Insuline dégludec sous toutes les formes protégéespar le brevet de base
LU92226C LU92226I2 (fr) 2003-08-05 2013-06-19 Combination d'insuline dégludec et insuline asparte sous toutes les formes protégées par le brevet de base

Family Applications After (1)

Application Number Title Priority Date Filing Date
LU92226C LU92226I2 (fr) 2003-08-05 2013-06-19 Combination d'insuline dégludec et insuline asparte sous toutes les formes protégées par le brevet de base

Country Status (18)

Country Link
US (3) US7615532B2 (fr)
EP (3) EP1660531A2 (fr)
JP (1) JP4463814B2 (fr)
KR (1) KR101159559B1 (fr)
AU (2) AU2004261353B2 (fr)
BE (2) BE2013C035I2 (fr)
BR (1) BRPI0413276B8 (fr)
CA (1) CA2531988C (fr)
CY (3) CY1113850T1 (fr)
FR (1) FR13C0035I2 (fr)
HU (1) HUS1300033I1 (fr)
IL (1) IL172980A (fr)
LU (2) LU92213I2 (fr)
MX (1) MXPA06001283A (fr)
NO (3) NO340925B1 (fr)
PL (1) PL2107069T3 (fr)
RU (1) RU2518460C2 (fr)
WO (1) WO2005012347A2 (fr)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0412252A (pt) * 2003-07-25 2006-09-19 Conjuchem Inc derivados de insulina de longa duração e métodos dos mesmos
CA2531988C (fr) * 2003-08-05 2016-06-28 Novo Nordisk A/S Nouveaux derives de l'insuline
ES2490243T3 (es) * 2005-02-02 2014-09-03 Novo Nordisk A/S Derivados de insulina
WO2006082204A1 (fr) * 2005-02-02 2006-08-10 Novo Nordisk A/S Derives d'insuline
PT1969004E (pt) 2005-12-28 2011-11-25 Novo Nordisk As Composições que compreendem uma insulina acilada e zinco e método para criar tais composições
ES2387955T3 (es) 2006-02-27 2012-10-04 Novo Nordisk A/S Derivados de insulina
WO2007104736A2 (fr) * 2006-03-13 2007-09-20 Novo Nordisk A/S Insuline monocaténaire acylée
EP2015722B1 (fr) 2006-04-28 2016-11-16 Avent, Inc. Pansements pour site antimicrobien
BRPI0712041A2 (pt) * 2006-05-09 2011-12-27 Novo Nordisk As derivado de insulina
EP2024390B1 (fr) * 2006-05-09 2015-08-19 Novo Nordisk A/S Dérivé insulinique
CN101437849B (zh) * 2006-05-09 2015-09-30 诺沃-诺迪斯克有限公司 胰岛素衍生物
JP5097900B2 (ja) * 2006-06-27 2012-12-12 独立行政法人物質・材料研究機構 有機酸又はこれらの誘導体の活性エステル体の製造方法
WO2008015099A2 (fr) 2006-07-31 2008-02-07 Novo Nordisk A/S Insulines pegylées à extensions
KR101729986B1 (ko) 2006-09-22 2017-04-25 노보 노르디스크 에이/에스 프로테아제 내성 인슐린 유사체
WO2008132224A2 (fr) 2007-04-30 2008-11-06 Novo Nordisk A/S Procédé de déshydratation d'une composition de protéine, composition de protéine déshydratée et composition pharmaceutique contenant la protéine déshydratée
CN101677944A (zh) * 2007-06-01 2010-03-24 诺沃-诺迪斯克有限公司 稳定的非含水药物组合物
EP2514406A1 (fr) 2007-06-01 2012-10-24 Novo Nordisk A/S Préconcentrés spontanément dispersibles comprenant un médicament peptidique dans un support solide ou semi-solide
WO2008152106A1 (fr) * 2007-06-13 2008-12-18 Novo Nordisk A/S Formulation pharmaceutique contenant un dérivé d'insuline
ES2526924T3 (es) 2007-08-15 2015-01-16 Novo Nordisk A/S Insulinas con una fracción acilo que comprende unidades repetitivas de aminoácidos que contienen alquilenglicol
ES2548304T3 (es) 2007-08-15 2015-10-15 Novo Nordisk A/S Análogos de la insulina que contienen una fracción acilo y alquilenglicol
CN101157725B (zh) * 2007-10-24 2012-07-25 中国药科大学 人胰岛素类似物的制备方法及用途
JP5715418B2 (ja) * 2007-11-08 2015-05-07 ノボ・ノルデイスク・エー／エス インスリン誘導体
DK2597103T3 (en) 2007-11-16 2017-02-13 Novo Nordisk As Stable pharmaceutical compositions comprising liraglutide and degludec
WO2009112583A2 (fr) 2008-03-14 2009-09-17 Novo Nordisk A/S Analogues de l’insuline stabilisés une protéase
MX2010009850A (es) 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
ES2561208T3 (es) 2008-09-12 2016-02-25 Novo Nordisk A/S Método de acilación de un péptido o una proteína
US9603904B2 (en) * 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
AU2010207721B2 (en) 2009-01-23 2015-03-26 Novo Nordisk A/S FGF21 derivatives with albumin binder A-B-C-D-E- and their use
CN102666579A (zh) 2009-10-30 2012-09-12 诺沃—诺迪斯克有限公司 降钙素基因相关肽的衍生物
CA2786953A1 (fr) * 2010-01-12 2011-07-21 Florian Anders Foeger Compositions pharmaceutiques pour l'administration orale de peptides de l'insuline
EP2536752B1 (fr) 2010-02-16 2015-04-08 Novo Nordisk A/S Facteur VIII, modfié et recombiné
EP2536434B1 (fr) 2010-02-16 2016-04-20 Novo Nordisk A/S Procédé de purification
ES2612468T3 (es) 2010-05-10 2017-05-17 Novo Nordisk A/S Procedimiento para la preparación de complejos de insulina-zinc
EP2576588A4 (fr) 2010-05-25 2014-07-09 Syngene Ltd Procédés de synthèse de ponts dicarba contenant des alcynes dans des peptides
CN102985440B (zh) 2010-06-23 2016-10-26 诺沃-诺迪斯克有限公司 包含额外的二硫键的胰岛素衍生物
CN102947331B (zh) 2010-06-23 2016-08-03 诺沃—诺迪斯克有限公司 包含额外的二硫键的胰岛素类似物
CN102933599A (zh) 2010-06-23 2013-02-13 诺沃—诺迪斯克有限公司 包含额外的二硫键的人胰岛素
JP2013540771A (ja) 2010-10-15 2013-11-07 ノヴォ ノルディスク アー／エス 新規ｎ末端修飾インスリン誘導体
CN103167878A (zh) * 2010-10-27 2013-06-19 诺沃—诺迪斯克有限公司 采用在不同注射时间间隔给予的胰岛素注射剂治疗糖尿病
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
JP2013545782A (ja) 2010-12-14 2013-12-26 ノヴォ ノルディスク アー／エス 長時間作用型インスリンと組み合わせた速効型インスリン
US20140011728A1 (en) 2011-02-15 2014-01-09 Novo Nordisk A/S Long-acting il-1 receptor antagonists
RU2013145013A (ru) * 2011-03-28 2015-05-10 Ново Нордиск А/С Новые аналоги глюкагона
US20140056953A1 (en) 2011-04-14 2014-02-27 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
JP6058646B2 (ja) 2011-06-15 2017-01-11 ノヴォ ノルディスク アー／エス 多置換インスリン
AR088161A1 (es) * 2011-09-23 2014-05-14 Novo Nordisk As Analogos de glucagon
AU2012350586B2 (en) * 2011-12-15 2017-02-02 Jiangsu Hengrui Medicine Co., Ltd. Human insulin analogue and acylated derivative thereof
EP2794648A1 (fr) 2011-12-21 2014-10-29 Novo Nordisk A/S Dérivés de l'insuline modifiés à leur extrémité n-terminale
WO2013153000A2 (fr) 2012-04-11 2013-10-17 Novo Nordisk A/S Formulations à base d'insuline
US20160031962A1 (en) * 2012-04-20 2016-02-04 Kleomenis K. Barlos Solid phase peptide synthesis of insulin using side chain achored lysine
WO2013164375A1 (fr) 2012-05-01 2013-11-07 Novo Nordisk A/S Composition pharmaceutique
EP2869830B1 (fr) 2012-07-09 2016-10-12 Novo Nordisk A/S Nouvelle utilisation de dérivés de l'insuline
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP6285447B2 (ja) 2012-10-17 2018-02-28 ノヴォ ノルディスク アー／エス 経口ペプチド送達用の脂肪酸アシル化ｄ−アミノ酸
BR112015014800A2 (pt) 2012-12-21 2017-10-10 Sanofi Sa derivados da exendina-4 funcionalizada
EP2976096B1 (fr) * 2013-03-20 2019-02-27 Novo Nordisk A/S Régime de dosage pour insuline
CN105307672B (zh) 2013-04-18 2021-01-05 诺和诺德股份有限公司 用于医学用途的稳定、延长的glp-1/胰高血糖素受体共激动剂
WO2014177623A1 (fr) 2013-04-30 2014-11-06 Novo Nordisk A/S Schéma d'administration d'un nouveau type
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
KR20160065126A (ko) 2013-10-07 2016-06-08 노보 노르디스크 에이/에스 인슐린 유사체의 신규한 유도체
FR3013049B1 (fr) 2013-11-14 2015-11-13 You-Ping Chan Analogue de l'insuline glargine
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086729A1 (fr) 2013-12-13 2015-06-18 Sanofi Agonistes mixtes des récepteurs glp-1/gip
WO2015086730A1 (fr) 2013-12-13 2015-06-18 Sanofi Analogues peptidiques de l'exendine 4 non acylés
BR112016016321A2 (pt) 2014-02-18 2017-10-03 Novo Nordisk As Derivados de análogos de glucagon estáveis, seus usos, e composição farmacêutica
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
CN106536547A (zh) 2014-06-04 2017-03-22 诺和诺德股份有限公司 用于医疗用途的glp‑1/胰高血糖素受体共激动剂
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
US20190010206A1 (en) 2015-08-25 2019-01-10 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
US20180244743A1 (en) 2015-08-25 2018-08-30 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
TWI747929B (zh) * 2016-08-02 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 一種人胰島素或其類似物的醯化衍生物
WO2018096163A1 (fr) 2016-11-28 2018-05-31 Novo Nordisk A/S Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme
WO2018096164A1 (fr) 2016-11-28 2018-05-31 Novo Nordisk A/S Insuline dégludec pour le traitement du diabète
EP3544683A1 (fr) 2016-11-28 2019-10-02 Novo Nordisk A/S Insuline dégludec utilisée dans des conditions cardiovasculaires
SI3554534T1 (sl) 2016-12-16 2021-09-30 Novo Nordisk A/S Farmacevtski sestavki, ki vsebujejo inzulin
JOP20190273A1 (ar) 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
RU2020128190A (ru) 2018-02-09 2022-03-09 Цзянсу Хэнжуй Медицин Ко., Лтд. Кодон-оптимизированный ген предшественника и ген сигнального пептида аналога человеческого инсулина
CA3100869A1 (fr) 2018-05-24 2019-11-28 Jiangsu Hengrui Medicine Co., Ltd. Procede de preparation d'un precurseur d'insuline humaine recombinee ou d'un analogue associe
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
WO2020002428A1 (fr) 2018-06-26 2020-01-02 Novo Nordisk A/S Système fournissant des recommandations de dose pour le titrage de l'insuline basale
KR20200017078A (ko) 2018-08-08 2020-02-18 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
KR20200080747A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
KR20200080748A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법
TW202120536A (zh) 2019-07-31 2021-06-01 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
WO2021136296A1 (fr) 2019-12-30 2021-07-08 甘李药业股份有限公司 Dérivé d'insuline
WO2023084118A1 (fr) 2021-11-15 2023-05-19 Adocia Compositions solides comprenant un peptide ou une protéine et un acide aminé acylé
EP4180060A1 (fr) 2021-11-15 2023-05-17 Adocia Compositions solides comportant un peptide ou une protéine et un acide aminé acylé
EP4299057A1 (fr) 2022-06-30 2024-01-03 Adocia Compositions solides comportant un peptide ou une protéine et un acide aminé acylé
EP4299071A1 (fr) 2022-07-01 2024-01-03 Adocia Compositions comprenant un peptide ou une protéine et un acide aminé acylé

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1212679B (de) 1957-08-03 1966-03-17 Novo Terapeutisk Labor As Verfahren zur Herstellung von Insulinloesungen
GB1042194A (en) 1962-04-30 1966-09-14 Olin Mathieson Insulin preparations
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3868358A (en) 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
GB1492997A (en) 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
JPS5767548A (en) 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
DE3827533A1 (de) 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
DK0506792T3 (da) 1989-12-21 1995-10-09 Novo Nordisk As Insulinpræparat, der indeholder nikotinsyre eller nikotinamid
DK45590D0 (fr) 1990-02-21 1990-02-21 Novo Nordisk As
JP3193398B2 (ja) 1991-07-23 2001-07-30 サンデン株式会社 ショ−ケ−ス
DE10399015I1 (de) 1991-12-20 2012-05-03 Novo Nordisk As Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
ES2163451T3 (es) 1993-09-17 2002-02-01 Novo Nordisk As Insulina acilada.
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
WO1996010417A1 (fr) 1994-10-04 1996-04-11 Novo Nordisk A/S Preparations contenant l'insuline humaine aspb28 et du nicotinamide
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5830999A (en) 1995-01-26 1998-11-03 Regents Of The University Of California Stabilization of insulin through ligand binding interations
US6251856B1 (en) * 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
HUP9800523A3 (en) 1995-03-17 1998-09-28 Novo Nordisk As Insulin derivatives
ES2434840T3 (es) 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
US6451970B1 (en) * 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5898267A (en) * 1996-04-10 1999-04-27 Mcdermott; Kevin Parabolic axial lighting device
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US5905140A (en) 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
WO1998002460A1 (fr) * 1996-07-11 1998-01-22 Novo Nordisk A/S Procede selectif d'alcylation
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
ATE264871T1 (de) 1996-07-26 2004-05-15 Aventis Pharma Gmbh Insulinderivate mit erhöhter zinkbindung
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
HUP0000547A3 (en) * 1997-03-20 2002-11-28 Novo Nordisk As Zinc free insulin crystals for use in pulmonary compositions
WO1998042368A1 (fr) 1997-03-20 1998-10-01 Novo Nordisk A/S Formulation de poudre therapeutique destinee a etre administree dans les voies respiratoires et contenant de l'insuline cristalline
AU6611898A (en) 1997-03-20 1998-10-20 Novo Nordisk A/S Method for preparation of a therapeutic powder through coprecipitation of insulin and absorption enhancer
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
SI0884053T1 (en) 1997-06-13 2003-02-28 Eli Lilly And Company Stable insulin formulations
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
UA69393C2 (uk) * 1997-10-24 2004-09-15 Ново Нордіск А/С Водорозчинний агрегат похідної інсуліну
WO1999021578A1 (fr) 1997-10-24 1999-05-06 Eli Lilly And Company Compositions d'insuline insolubles
US20020155994A1 (en) 1997-10-24 2002-10-24 Svend Havelund Aggregates of human insulin derivatives
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
AU1870099A (en) 1998-01-09 1999-07-26 Novo Nordisk A/S Stabilised insulin compositions
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
KR100617286B1 (ko) 1998-10-16 2006-08-30 노보 노르디스크 에이/에스 폐 송달을 위한 안정한 농축 인슐린 조제물
US6586573B1 (en) 1999-02-22 2003-07-01 Baxter International Inc. Albumin-free Factor VIII formulations
CA2370302A1 (fr) 1999-04-27 2000-11-02 Benjamin Lee Hughes Cristaux d'insuline destines a une administration pulmonaire
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE60224284T2 (de) 2001-06-28 2008-12-18 Novo Nordisk A/S Stabile formulierung von modifiziertem glp-1
IL161848A0 (en) 2001-12-20 2005-11-20 Lilly Co Eli Insulin moldecule having protracted time action
WO2003075950A1 (fr) 2002-03-13 2003-09-18 Novo Nordisk A/S Procede servant a limiter la prise de poids au moyen d'un traitement a l'insuline
WO2003094956A1 (fr) 2002-05-07 2003-11-20 Novo Nordisk A/S Preparations solubles comprenant de l'insuline monomere et de l'insuline acylee
US20050232899A1 (en) 2002-05-31 2005-10-20 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
KR100615389B1 (ko) 2002-08-23 2006-08-25 (주)헬릭서 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품
MXPA05004593A (es) 2002-10-29 2005-07-26 Alza Corp Particulas de polipeptido estabilizado en estado solido.
US20040138099A1 (en) 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
AU2004210268B8 (en) 2003-02-07 2009-06-04 Ajinomoto Co., Inc. Therapeutic agents for diabetes
CN100422328C (zh) 2003-02-19 2008-10-01 诺瓦提斯公司 在人转移性肿瘤细胞中表达的糖蛋白抗原sima135
CA2518143A1 (fr) 2003-03-04 2004-09-16 The Technology Development Company Ltd. Systeme d'administration d'une therapie medicamenteuse et cellulaire
JP4658041B2 (ja) 2003-06-25 2011-03-23 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの液体組成物
US20050054818A1 (en) 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
EP2275439B1 (fr) 2003-08-05 2014-03-26 Novo Nordisk A/S Nouveaux dérivés d'insuline
CA2531988C (fr) 2003-08-05 2016-06-28 Novo Nordisk A/S Nouveaux derives de l'insuline
JP5653572B2 (ja) 2003-08-14 2015-01-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液状水性医薬組成物
EP1663295A2 (fr) 2003-09-01 2006-06-07 Novo Nordisk A/S Formulations de peptides stables
ES2229931B1 (es) 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
JP2007532096A (ja) 2003-11-14 2007-11-15 ノボ　ノルディスク　アクティーゼルスカブ アシル化されたインスリンの製造方法
ATE554792T1 (de) 2003-12-23 2012-05-15 Pharmacia Corp Stabiles wachstumshormon-flüssigformulierung
ATE433746T1 (de) 2004-03-12 2009-07-15 Biodel Inc Insulinzusammensetzungen mit verbesserter wirkstoffabsorption
CA2567309A1 (fr) 2004-06-01 2005-12-15 Ares Trading S.A. Procede de stabilisation de proteines
EP1796647B1 (fr) 2004-08-12 2010-08-11 Schering Corporation Preparation stable d'interferon pegyle
ES2395035T3 (es) 2004-08-17 2013-02-07 Regeneron Pharmaceuticals, Inc. Formulaciones de antagonistas de la IL-1
EP1814581B1 (fr) 2004-11-12 2016-03-16 Novo Nordisk A/S Preparations stables de peptides comprenant un analogue du glp-1 acyle et une insuline basale
EP1817049B1 (fr) 2004-11-22 2012-08-01 Novo Nordisk A/S Formulations solubles stables contenant de l'insuline et un sel de protamine
WO2006079019A2 (fr) 2005-01-21 2006-07-27 Alza Corporation Preparations peptidiques therapeutiques a stabilite accrue
WO2006082204A1 (fr) * 2005-02-02 2006-08-10 Novo Nordisk A/S Derives d'insuline
PT1969004E (pt) 2005-12-28 2011-11-25 Novo Nordisk As Composições que compreendem uma insulina acilada e zinco e método para criar tais composições
ES2387955T3 (es) 2006-02-27 2012-10-04 Novo Nordisk A/S Derivados de insulina
JP2009533471A (ja) 2006-04-12 2009-09-17 バイオデル， インコーポレイテッド 即効型および長時間作用型組合せインスリン製剤
BRPI0712041A2 (pt) 2006-05-09 2011-12-27 Novo Nordisk As derivado de insulina
WO2008152106A1 (fr) 2007-06-13 2008-12-18 Novo Nordisk A/S Formulation pharmaceutique contenant un dérivé d'insuline
DK2597103T3 (en) 2007-11-16 2017-02-13 Novo Nordisk As Stable pharmaceutical compositions comprising liraglutide and degludec
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物

Also Published As

Publication number Publication date
US8828923B2 (en) 2014-09-09
CY1113850T1 (el) 2015-11-04
HUS1300033I1 (hu) 2016-08-29
EP1660531A2 (fr) 2006-05-31
CY2013029I2 (el) 2015-11-04
EP2107069A3 (fr) 2009-11-25
CA2531988A1 (fr) 2005-02-10
RU2008152033A (ru) 2010-07-10
KR101159559B1 (ko) 2012-06-26
EP2264065A2 (fr) 2010-12-22
MXPA06001283A (es) 2006-04-11
LU92226I9 (fr) 2018-11-19
BE2013C035I2 (fr) 2023-12-14
AU2010200497A1 (en) 2010-03-04
JP4463814B2 (ja) 2010-05-19
BRPI0413276A (pt) 2006-10-10
LU92213I9 (fr) 2018-11-19
BE2013C038I2 (fr) 2023-12-14
IL172980A0 (en) 2006-06-11
US20140349925A1 (en) 2014-11-27
US7615532B2 (en) 2009-11-10
KR20060132543A (ko) 2006-12-21
JP2007523881A (ja) 2007-08-23
EP2264065A3 (fr) 2011-07-27
IL172980A (en) 2013-10-31
BRPI0413276B1 (pt) 2020-03-03
CY2013029I1 (el) 2015-11-04
US20100009899A1 (en) 2010-01-14
AU2004261353A1 (en) 2005-02-10
CA2531988C (fr) 2016-06-28
AU2004261353B2 (en) 2009-12-10
NO2018002I2 (no) 2018-08-20
CY2013027I2 (el) 2015-11-04
EP2107069A2 (fr) 2009-10-07
LU92226I2 (fr) 2015-04-29
NO2018003I1 (no) 2018-01-11
US20060183668A1 (en) 2006-08-17
AU2010200497B2 (en) 2014-10-23
NO340925B1 (no) 2017-07-17
BRPI0413276B8 (pt) 2021-05-25
FR13C0035I2 (fr) 2014-03-07
WO2005012347A2 (fr) 2005-02-10
FR13C0035I1 (fr) 2013-08-09
EP2107069B1 (fr) 2013-01-16
RU2518460C2 (ru) 2014-06-10
NO20061026L (no) 2006-03-02
PL2107069T3 (pl) 2013-06-28
NO2018002I1 (no) 2018-01-11
EP2264065B1 (fr) 2017-03-08
CY2013027I1 (el) 2015-11-04
WO2005012347A3 (fr) 2005-04-14

Similar Documents

Publication Publication Date Title
LU92213I2 (fr) Insuline dégludec sous toutes les formes protégéespar le brevet de base
LU92307I2 (fr) Elviégravir sous toutes ses formes comme protégéespar le brevet de base
LU92327I2 (fr) Ponatinib sous toutes ses formes telles que protégées par le brevet de base
DK1699821T3 (da) Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MED FORBEDREDE FARMAKOKINETIKKER
ATE395350T1 (de) Mit betainen stabilisierten aluminium-zirconium- glycin-antitranspirantien
EP1626981A4 (fr) Proteines protegees contre la dipeptidylpeptidase
DE602004032093D1 (de) Polierzusammensetzung
DE602004020302D1 (de) Motorhaubenstruktur
GB0301662D0 (en) Improvements in or relating to organic compounds
ATE455555T1 (de) Glp-1-analoga
GB0323685D0 (en) Improvements in or relating to organic compounds
DK1471124T3 (da) Politursammensætning
DE602004025173D1 (de) Hochauflösende Leichtgewichtlupe
GB0316190D0 (en) Improvements in or relating to organic compounds
DE602004001543D1 (de) Tintenzusammensetzung
DE502004004670D1 (de) Rückwirkungsanordnung
FR2851326B3 (fr) Hotte d'extraction
GB0324529D0 (en) Improvements in or relating to organic compounds
GB0301094D0 (en) Improvements in or relating to organic compounds
GB0401839D0 (en) Improvements in or relating to organic compounds
GB0317904D0 (en) Improvements in or relating to organic compounds
DE60310256D1 (de) Tintenzusammensetzung
ITRM20030246A1 (it) Peptidi dendritici multimerici come agenti biologici
ES1055367Y (es) Fregona perfeccionada
ES1054637Y (es) Colchoneta de playa perfeccionada